Accurate Prediction of Antibody Resistance in Clinical HIV-1 Isolates

Abstract excerpt

Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in prevention and treatment of HIV-1 infection with several undergoing clinical trials. Due to high sequence diversity and mutation rate of HIV-1, viral isolates are often resistant to particular bNAbs. Resistant strains are commonly identified by time-consuming and expensive in vitro neutralization expe...

Topics

Open a Topic to create a Post that cites this publication.

• HIV Research and Treatment
• vaccines and immunoinformatics approaches
• Antibodies, Neutralizing
• Broadly Neutralizing Antibodies
• Drug Resistance, Viral
• HIV/AIDS drug development and treatment
• HIV Antibodies
• HIV Infections

Identifiers and source

Literature Corpus work

bd9418da-f918-5814-bd3d-3a5191f12151

DOI

10.1101/364828